BiondVax Pharmaceuticals Ltd. (BVXV) |
| 1.36 0.01 (0.74%) 09-06 15:59 |
| Open: | 1.32 |
| High: | 1.36 |
| Low: | 1.31 |
| Volume: | 22,668 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.58 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.92 |
| Resistance 1: | 0.81 |
| Pivot price: | 0.69 |
| Support 1: | 0.62 |
| Support 2: | 0.52 |
| 52w High: | 11.49 |
| 52w Low: | 0.63 |
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Financials
| EPS | -2.350 |
| Book Value | -1.960 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -30.9 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 06 Jan 2023
BiondVax's Inhaled COVID-19 Therapy Eliminated SARS-COV-2 Virus In Preclinical Study; Stock Up - RTTNews
Wed, 21 Dec 2022
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) | FinancialContent - FinancialContent
Tue, 06 Dec 2022
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board - GlobeNewswire
Thu, 31 Mar 2022
BiondVax to host analyst and investor webinar on April 4th - BioSpace
Mon, 03 Jan 2022
Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) - FinancialContent
Fri, 23 Oct 2020
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate - BioSpace
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
